METHOD FOR THE IN VITRO DIAGNOSIS OF A NEURODEGENERATIVE DISEASE
By detecting beta-amyloid peptides and phosphorylated tau proteins in stool samples, the method provides a non-invasive and sensitive early diagnosis and monitoring of neurodegenerative diseases, enabling timely intervention and effective treatment.
Patent Information
- Application Number
- FR2023004537
- Authority / Receiving Office
- FR · FR
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-05
- Publication Date
- 2024-11-08
AI Technical Summary
Current diagnostic methods for neurodegenerative diseases like Alzheimer's disease are invasive, costly, and lack sensitivity for early detection, leading to delayed intervention and ineffective treatments.
Detection of beta-amyloid peptides (Aβ) and phosphorylated tau proteins (P-tau) in stool samples using specific antibodies to form complexes, providing a non-invasive and sensitive early diagnosis and monitoring of neurodegenerative diseases.
The method offers early and reliable detection of neurodegenerative diseases, allowing for timely intervention and effective treatment monitoring through stable biomarkers in stool samples.
Smart Images

Figure 00000017_0000 
Figure 00000017_0001 
Figure 00000018_0000
Abstract
Description
Title of the invention: METHOD FOR THE IN VITRO DIAGNOSIS OF A NEURODEGENERATIVE DISEASE
[0001] The present invention relates to the detection of neurodegenerative diseases (NDD), and more specifically to the detection of these diseases at an early stage.
[0002] Neurodegenerative disease is a chronic, progressive disease that affects the nervous system and leads to irreversible cognitive, behavioral, sensory, and motor disorders. Alzheimer's disease is the most common form of dementia in humans, accounting for 60 to 70% of cases of dementia, followed by Parkinson's disease, followed by diseases such as Lou Gehrig's disease and Huntington's disease. They are all characterized by a progressive loss of neuron function and by a major risk factor: aging.
[0003] Several neurodegenerative diseases and in particular the aforementioned diseases are classified as proteinopathies, in that they are associated with the presence of proteins in an abnormally aggregated and / or misfolded form, the accumulation of which in the brain leads to toxicity. Belonging to this group of pathologies are tauopathies which have in common an abnormal accumulation of tau proteins in the form of clusters and which share clinical and pathological similarities. The invention relates to the diagnosis of such diseases and particularly those associated with at least one of the amyloid beta and tau proteins.
[0004] The present invention is described with reference to tauopathies, in particular Alzheimer's disease, but it is not limited thereto and extends to all MNDs meeting the above definition.
[0005] Alzheimer's disease (AD) is an incurable neurodegenerative disease that begins with a long asymptomatic phase and is characterized by a progressive decline in cognitive abilities accompanied by neuronal and synaptic loss.
[0006] There is currently no curative treatment for Alzheimer's disease and the failure of the latest therapeutic strategies results largely from a late diagnosis of the disease when the first characteristic signs are already visible.
[0007] The diagnosis of AD has, however, evolved considerably in recent years with the identification of the concomitant presence of two types of cerebral lesions, characteristic of the disease: extracellular deposits of amyloid peptides (A[3], in particular A[342, designated as amyloid plaques or senile plaques, and intraneuronal deposits of hyperphosphorylated tau proteins (P-tau), associated with neurofibrillary degeneration (NFD). Thus, to date, the detection of AD relies on neuropsychological tests, the measurement of amyloid peptides and hyperphosphorylated tau proteins in cerebrospinal fluid (CSF), morphological imaging (MRI) and positron emission tomography (PET) technology to detect functional (radioactive fluorodeoxyglucose PET or 18FDG) or molecular (amyloid PET and tau PET) tracers.
[0008] Detection of AD markers, A[3 and tau, is performed in CSF because it contains proteins from the brain, but CSF collection can be difficult depending on the patient's age and health status because it requires a lumbar puncture, an invasive procedure.
[0009] The interest of these markers lies in their synergistic use to refine the positive diagnosis and begin to provide prognostic information to the patient. However, even if they are very sensitive and specific for the positive diagnosis and for detecting pathophysiological lesions from the stage of memory complaints or minor cognitive disorders, well before cognitive decline and loss of autonomy, the diagnosis occurs at the clinical phase of AD, whereas it is preceded by a preclinical phase of the order of 20 years, or even more, during which no or only subtle symptoms of the disease are observed. The identification of markers in this early phase of the disease would allow:
[0010] 1) to delay the onset of the disease or even prevent AD dementia; indeed, current treatments can only help improve clinical symptoms, but cannot delay or reverse the progression of AD;
[0011] 2) an intervention further upstream of therapeutic strategies which could have better efficiency; and
[0012] 3) systematic monitoring of patients and the effectiveness of treatments.
[0013] Studies have been conducted on the detection of a molecular signature of AD in a bodily fluid such as blood or saliva, which can be collected in a minimally invasive manner.
[0014] Regarding the A[3 marker, this is produced in the brain and is indeed present in blood plasma. However, it is also produced in platelets and peripheral tissues, making it difficult to distinguish, in plasma, between TA[3 originating from the brain and that produced. In addition, plasma concentrations of A[342 are at least 100 times lower than in CSF (typically, of the order of a few pg / ml) and are diluted by the high concentration of other non-specific protein components. Finally, plasma A[3 peptides, due to their hydrophobic nature, tend to bind to erythrocytes and other plasma proteins, which is likely to lead to masking of the epitopes and thus prevent detection of the peptides.
[0015] As for the P-tau marker, secreted in the CSF, it is also present in blood plasma. A semi-sensitive test for this marker phosphorylated on threonine 181 (similar to the most widely used CSF test) with detection by electrochemiluminescence has been developed. This test has shown that the plasma concentration of P-tau was higher in patients with Alzheimer's dementia than in controls (2 to 4 times). This increase appears in the early (preclinical) phase of the disease, but can also arise in other circumstances episodically such as acute hypoxic brain injuries in the case of concussion and during anesthesia, which has led to this test being discarded.
[0016] Other candidate proteins in the blood have been found by the proteomic approach (Kitamura Y. et al., Plasma protein profiling for potential biomarkers in the early diagnosis of Alzheimer's disease, Neurological Research. Taylor & Francis, 39(3), pp231-238, (2017) but they did not provide satisfactory results.
[0017] To date, there remains a crucial need to identify viable markers for AD that track disease progression over time and whose concentrations can change in response to disease treatment.
[0018] It has been surprisingly discovered that a viable and reliable molecular signature of AD is present in the stool of a human or an animal. These markers are beta-amyloid peptides (A[3) and phosphorylated tau proteins (P-tau) and their respective derived forms, variations of which make it possible to characterize an early stage of proteinopathy-type neurodegenerative disease such as tauopathy, and in particular Alzheimer's disease.
[0019] Thus the invention relates to a method for the in vitro diagnosis of a neurodegenerative disease, in a human or animal individual, comprising the step which consists in detecting the presence of at least one marker chosen from beta-amyloid peptides (A[3), the derived forms of said peptides, phosphorylated tau proteins (P-tau) and the derived forms of said proteins, in a stool sample of said individual. According to one implementation of the method of the invention, the neurodegenerative disease is a tauopathy, and the presence of at least one marker chosen from phosphorylated tau proteins and their derived forms is detected in a stool sample of said individual. According to another implementation of the method of the invention, the presence of at least one marker chosen from beta-amyloid peptides and their derived forms, and of at least one marker chosen from phosphorylated tau proteins and their derived forms, is determined.
[0020] In all the objects of the invention described in the present text, the expression "at least one marker chosen from beta-amyloid peptides (A[3), the forms derived from said peptides, phosphorylated tau proteins (P-tau) and the forms derived from said proteins”, it should be understood that said object involves one or more markers chosen indifferently from beta-amyloid peptides (A[3), the derived forms of said peptides, phosphorylated tau proteins (P-tau) and the derived forms of said proteins. When it involves several markers, any combination of these can be envisaged.
[0021] The detection of these markers in stools, which has the advantage of being less invasive and less expensive than their detection in CSF, is also reproducible and sensitive. Unexpectedly, it proves to be specific for the early diagnosis of AD, and even capable of revealing subjects at risk of developing AD. In addition, the biomarkers analyzed at the end of the sample were found to be stable over time and their concentration does not vary up to 7 days post-sampling, indicating that there is little or no degradation of the sample during this period.
[0022] The present invention makes a real contribution to the diagnosis of neurodegenerative diseases, such as Alzheimer's disease.
[0023] As mentioned above, beta-amyloid peptides (A[3) and phosphorylated tau proteins are a group of known and well-identified molecules. Their definitions are recalled below.
[0024] Beta-amyloid peptide (A[3]) is a structure of 38 to 42 amino acids resulting from the enzymatic cleavage of the amyloid precursor protein (APP) involving beta- or gamma-secretase enzymes. The gene coding for this protein is located on chromosome 21. The beta-amyloid peptide, which is soluble, has the ability to oligomerize to give oligomers of different sizes and to aggregate to form fibrillar amyloid plaques, which are insoluble. Thus, by derived form of the beta-amyloid peptide, we mean the oligomers of the beta-amyloid peptide regardless of their size, and the fibrillar aggregated forms (Chen, Gf., et al. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin 38, 1205-1235 (2017). It should be noted that, according to a particular implementation of the invention, namely detection by DotBlot, these different conformations can be distinguished.This is an additional advantage for the invention, because the oligomeric forms, which are not yet aggregated, are the most toxic. In the definition of derived form of peptide A[3, also included are modified peptides resulting from one or more post-translational modifications such as a truncated peptide A[3.
[0025] Tau protein is a protein encoded by the microtubule-associated protein tau (MAPT) gene on human chromosome 17 and is described in Xia et al. Molecular Neurodegeneration 16, 37 (2021). It is a water-soluble protein, it has approximately 80 potential phosphorylation sites, on the amino acids serine and threonine. In a healthy individual, some of these sites are phosphorylated in the physiological conditions, but in certain pathological conditions, and in particular in MND, the protein is highly phosphorylated (referred to as P-tau, phosphorylated tau protein or hyperphosphorylated tau protein). According to the invention, phosphorylated tau protein means an abnormal phosphorylation of certain previously identified key sites of the tau protein. By derived form of phosphorylated tau protein, we understand the hyperphosphorylated forms found on pathological sites, aggregated tau proteins and modified proteins resulting from one or more post-translational modifications such as a truncated tau protein.
[0026] The derived forms of peptide A[3 or tau protein resulting from post-translational modification(s) are a concept known to those skilled in the art. As examples, reference may be made to the following articles:
[0027] Carroll T, Guha S, Nehrke K and Johnson GVW; Tau Post-Translational Modifications: Potentiators of Selective Vulnerability in Sporadic Alzheimer's Disease. Biology 2021, 10, 1047;
[0028] Alquezar C, Arya S and Kao AW; Tau Post-translational Modifications: Dynamic Transformers of Tau Function, Degradation, and Aggregation. Front. Neurol. 2021, 11:595532; and
[0029] Barykin EP, Mitkevich VA, Kozin SA and Makarov AA; Amyloid [3 Modification: A Key to the Sporadic Alzheimer's Disease? Forehead. Broom. 2017, 8:58.
[0030] Peptide A[3 and tau protein are water-soluble entities; as indicated previously, they tend to form oligomers which, as they increase in size, become less and less water-soluble to evolve into aggregates which are insoluble in an aqueous medium.
[0031] As a marker chosen from beta-amyloid peptides (A[3) and phosphorylated tau proteins (P-tau), as well as their respective derived forms, it is understood that they are in the free state, or in a state combined with one or more other entities such as other proteins / peptides, not preventing their detection.
[0032] According to a preferred implementation of each of the methods, kit and uses of the invention, at least one marker chosen from beta-amyloid peptides and their derived forms, and at least one marker chosen from phosphorylated tau proteins and their derived forms, is detected.
[0033] By early stage according to the invention, is meant a stage at which the mild symptoms of dementia have not yet appeared or appear, without a direct link having been established with a neurodegenerative disease. By way of example, it may correspond to the stage at which the first memory disorders are detected or at which other disorders are observed, in particular during screening campaigns such as those implemented from the age of 50 for cancers.
[0034] In one variant, the method of the invention comprises the following steps:
[0035] said stool sample of said individual is brought into contact with at least one antibody or part of an antibody specifically recognizing at least one of said markers, under conditions allowing the formation of a complex between said antibody or part of an antibody and said marker, and
[0036] the presence of a said complex is detected, where appropriate, the presence of a said complex determining whether the individual is affected by a neurodegenerative disease.
[0037] According to a variant of the invention, this method allows the in vitro diagnosis of Alzheimer's disease in an individual.
[0038] As stated previously, one of the advantages of the invention is to obtain an early diagnosis. In this respect, the individual tested may be asymptomatic or present some minor cognitive disorders which may not be directly associated with MND.
[0039] The invention also relates to a method for monitoring the condition of a human or animal individual suspected of suffering from a neurodegenerative disease, comprising the following steps:
[0040] a first stool sample from said individual is brought into contact with at least one antibody or part of an antibody specifically recognizing at least one marker chosen from beta-amyloid peptides, forms derived from said peptides, phosphorylated tau proteins and forms derived from said proteins, under conditions allowing the formation of a complex between said antibody or part of an antibody and said marker,
[0041] the content of a said complex in the first sample is measured,
[0042] then a second stool sample of said individual is brought into contact, said second sample being taken after the first sample, in the presence of said antibody or part of antibody, under conditions allowing the formation of a complex between said antibody or part of antibody and said marker,
[0043] the content of a said complex in the second sample is measured, a variation between the contents of said complex in the first sample and in the second sample, indicating a progression of the disease or a regression of the disease.
[0044] In a variant of this method,
[0045] the antibody or part of an antibody specifically recognizes at least one beta-amyloid peptide or a form derived from a beta-amyloid peptide and forms a complex therewith, and
[0046] a content of said complex in the second sample higher than the content of this same complex in the first sample indicates progression of the disease, at an early stage, or
[0047] a content of said complex in the second sample lower than the content of this same complex in the first sample indicates a regression of the disease.
[0048] According to another variant of a method for monitoring the condition of an individual, which can be combined with the previous one,
[0049] the antibody or part of an antibody specifically recognizes at least one soluble phosphorylated tau protein or a form derived from a phosphorylated tau protein and forms a complex therewith, and
[0050] a content of said complex in the second sample higher than the content of this same complex in the first sample indicates progression of the disease, at an early stage, or
[0051] a content of said complex in the second sample lower than the content of this same complex in the first sample indicates a regression of the disease.
[0052] The method for monitoring the condition of a human or animal individual suspected of being affected by a neurodegenerative disease as presented above is preferably included at an early stage of the disease up to a stage where the individual presents disorders which have just been associated with an MND, as opposed to a late stage of the disease. It has indeed been observed that at a late stage of the disease, an individual may undergo alterations in the elimination of plaques, which results in a decrease in the content of markers of the invention in the stool, which, at this stage, should not be interpreted as a regression of the disease.
[0053] Any of the variants of a monitoring method above can be implemented on a stool sample from an individual treated for said disease, making it possible in particular to evaluate the effectiveness of the treatment.
[0054] Thus, the invention also relates to a method for screening a drug for treating a neurodegenerative disease, in an individual suspected of suffering from such a disease, comprising the following steps:
[0055] a first stool sample from said individual is brought into contact with at least one antibody or part of an antibody specifically recognizing at least one marker chosen from beta-amyloid peptides, forms derived from said peptides, phosphorylated tau proteins and forms derived from said proteins, under conditions allowing the formation of a complex between said antibody or part of an antibody and said marker,
[0056] the content of a said complex in the first sample is measured,
[0057] then a second stool sample of said individual is brought into contact, said second sample being taken after the first sample, in the presence of said antibody or part of antibody, under conditions allowing the formation of a complex between said antibody or part of antibody and said marker,
[0058] the content of a said complex in the second sample is measured, a variation between the contents of said complex in the first sample and of said complex in the second sample, indicating the effectiveness or ineffectiveness of said drug.
[0059] In a variant of this method,
[0060] the antibody or part of an antibody specifically recognizes at least one beta-amyloid peptide or a derived form of a beta-amyloid peptide and forms a complex therewith, and
[0061] the content of said complex in the second sample lower than the content of this complex in the first sample indicates an effectiveness of the drug.
[0062] In another variant of the method, which can be combined with the above variant(s),
[0063] the antibody or antibody part specifically recognizes at least one phosphorylated tau protein or a derived form of a soluble phosphorylated tau protein and forms a complex therewith, and
[0064] a content of said complex in the second sample lower than the content of this complex in the first sample indicates an effectiveness of the drug.
[0065] The time between the collection of the first and second samples will vary depending on the method used. Thus, in a method for monitoring the condition of an individual undergoing therapeutic treatment, this time may be short and the method repeated more frequently than in a method for diagnosis. However, since the method is non-invasive, it is possible to multiply the samples for individualized and close monitoring.
[0066] The invention further relates to a kit for the in vitro detection of a neurodegenerative disease, at the early stage, of a human or animal individual, comprising
[0067] at least one antibody or part of an antibody specifically recognizing at least one marker chosen from beta-amyloid peptides (A[3), the forms derived from said peptides, the phosphorylated tau proteins and the forms derived from said proteins, and
[0068] the means allowing the extraction, from a stool sample of said individual, of at least one marker chosen from beta-amyloid peptides (A[3), the derived forms, the phosphorylated tau proteins and the derived forms of said proteins, and the formation of a complex between said antibody or part of antibody and said marker,
[0069] The invention also relates to the use of a marker chosen from beta-amyloid peptides, the derived forms of said peptides, the phosphorylated tau proteins and the derived forms of said proteins, for the in vitro diagnosis of a neurodegenerative disease, in an individual, said marker being detected in the stool of said individual. According to one use of the invention, the diagnosis is carried out at an early stage of the disease. In particular, it is intended for the in vitro diagnosis of Alzheimer's disease.
[0070] The present invention is illustrated in the following example and with the support of the figures according to which:
[0071] [Fig.l] and [Fig.2] represent the quantity, determined by densitometric analysis and expressed as relative intensity, of toxic oligomeric amyloid peptides (E22P), prefibrillar amyloid peptides (OC) and P-tau proteins (Tau-Pn"lxl, Tau-P Thr205^ cp a fraction of soluble peptides and proteins [Fig.l] and a fraction of insoluble peptides and proteins [Fig.2], extracted from feces of wild-type mice (WT) and AD transgenic mice (APP / PS1-21), as a function of time expressed in months: at 1 month, Fig. 1A and Fig. 2A; at 4 months, Fig. 1B and Fig. 2B; at 6 months, Fig. 1C and Fig. 2C; at 9 months, Fig. 1D and Fig. 2D. Example
[0072] In a transgenic (TG) mouse model of Alzheimer's disease (AD) (APP / PS1-21 mice), the temporal progression (from 1 to 9 months) of AD was monitored in the feces, brain, and intestines, respectively. 1) Follow-up in the stool
[0073] Feces from wild-type (WT) mice and APP / PS1 mice were collected and proteins from these samples were extracted. Operating mode 1.1) Stool recovery
[0074] The mice are placed in a clean cage for two hours after which the droppings are collected and counted before being frozen at -80°C. Then the samples are thawed, 5-6 droppings (100 mg) are transferred into a tube and placed overnight in an incubator at 56°C to be dehydrated. The dry material is weighed again to determine the % water which partly reflects intestinal function. 1.2) Protein extraction
[0075] The dried stools are taken up in 1 ml of RIPA buffer (50 mM Tris-HCl pH8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS) containing a cocktail of protease and phosphatase inhibitors. The homogenate is incubated for 10 minutes on ice before being subjected to 5 sonication cycles under the following conditions: 10 seconds of sonication (Amplitude 45) + 10 seconds in ice. The homogenate is then centrifuged for 10 minutes at 4°C at 14,000 rpm. The supernatant is collected in a clean tube. It contains the soluble proteins.
[0076] The pellet is resuspended in 1 mL of 5M guanidine HCl / 50 mM Tris-HCl pH 8 buffer containing a cocktail of protease and phosphatase inhibitors. The homogenate is again subjected to 5 sonication cycles under the following conditions: 10 seconds of sonication (Amplitude 45) + 10 seconds in ice. The homogenate is then centrifuged for 10 minutes at 4°C at 14,000 rpm. The supernatant is collected in a clean tube. It contains the insoluble proteins.
[0077] The protein content of each of the fractions is determined using the kit of BCA protein assay (Pierce™). 1.3) Analysis of fractions by DotBlot
[0078] Ten μg of proteins are absorbed by capillary action onto a nitrocellulose membrane (Biorad apparatus) and processed for DotBlot analysis with anti-toxic oligomeric amyloid peptide (A[3o, E22P), anti-fibrillar amyloid peptide (A[3-F, OC) and anti-Tau phosphorylated on Threonine 181 (pTauThr181) or Threonine 205 (pTau Thr205) antibodies. Normalization of the results is performed using an anti-GAPDH antibody or Tamido-black staining for the soluble fraction or after Ponceau Red staining for the insoluble fraction. 2) Monitoring in the brain and in the intestines
[0079] Proteins and peptides are recovered from different tissues and organs Procedure 2.1) Dissection
[0080] At the different ages studied, the mice were sacrificed by cervical dislocation. The brains and intestines of wild-type (WT) and APP / PS1 mice were collected. The brain was extracted from the skull and dissected to separate the cortex and hippocampus. The intestines were recovered and compartmentalized as follows: duodenum, jejunum, ileum, and colon.
[0081] These samples are separated into 2 batches before being frozen (in liquid nitrogen then stored at -80°C, in the OCT):
[0082] - one of the batches will be used for microscopic analysis after preparation of a section of 30 pm)
[0083] - the other batch will be used for biochemical experiments (Western Blot) or molecular biology (QPCR). 2.2) Protein extraction
[0084] The intestinal and brain samples are taken up in 1 ml of RIPA buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS) containing a cocktail of protease and phosphatase inhibitors. The tissues are ground using an automated program on a Milteny grinder. The homogenate is then centrifuged for 10 minutes at 4°C at 2,500 rpm. The supernatant is collected in a clean tube. It contains the proteins. The protein content of each of the fractions is determined using the BCA protein assay kit (Pierce™). 2.3) Analysis of lysates by Western Blot
[0085] Fifteen μg of protein are migrated on SDS-PAGE polyacrylamide gel (BioRad) at 100 volts for one hour and 30 minutes. The gel is then electrotransferred onto a polyvinylidene fluoride membrane (BioRad) and treated for analysis with anti-oligomeric amyloid peptide antibodies (A[3o, Ail), anti fibrillar amyloid peptide (A[3-F, OC) and anti-Tau phosphorylated on Threonine 205 (pTau™05) or Threonine 181 (pTau™81)- 2.4 Confocal microscopy
[0086] Paraformaldehyde (PFA)-fixed tissues from WT and APP / PS1 mice were immersed in 20% sucrose in PBS overnight, then frozen in chilled PFA and stored at -30°C. Sections (20-30 μm thick) were cut with a cryostat microtome (HM 500M, Microm). Sections were blocked by incubation with phosphate-buffered saline (PBS) containing 0.1% (v / v) Triton X100 and 3% BSA for 30 min at room temperature. The tissue sections were then incubated overnight at 4°C with primary antibodies directed against the different proteins of interest, washed 3 times with PBS containing 0.2% Tween20 (PBS-T) and incubated for 2 h at room temperature with the secondary antibodies conjugated to different fluorochromes.After three washes in PBS-T, nuclei were stained by incubation in Hoescht's solution (1:200) for 5 minutes and slides were mounted in fluorescent mounting medium (Dako). 2.5) Tracking in the brain
[0087] The morphological study of spines and synaptic density is carried out by confocal microscopy using the Thyl-eYFP APP / PS1-21 mouse model. The distribution of A[3 and P-tau proteins is also analyzed by confocal microscopy with antibodies specific for the different proteins. The presence of amyloid plaques is detected by confocal microscopy using thioflavin-T. The expression levels of these different proteins are determined by Western Blot, DotBlot and / or Elisa. 2.6) Follow-up in the intestines
[0088] As for the brain, the distribution of A[3 and P-tau proteins is analyzed by confocal microscopy with antibodies specific for the different proteins. This technique also makes it possible to understand the structure and morphology of the villi and intestinal crypts. The expression levels of these different proteins are determined by Western Blot, DotBlot. The inflammatory context will be validated by QPCR and Elisa assays of different cytokines. 3) Results
[0089] Analysis of fecal A[3 peptides (toxic oligomeric forms E22P and pre-fibrillar OC by specific conformational antibodies) and Tau-P Thr181 and Tau-PThr205 proteins revealed a significant difference in the soluble fractions extracted from the feces between WT and TG animals, from 1 month, before any detectable accumulation in the brain Fig. 1A. Indeed, transgenic mice eliminate signifi significantly more toxic A[3o (E22P), pTauThr181 and pTauThr205 than WT animals at 1 month. These differences are maintained at 2 months (results not shown). From 4 months Fig. 1B and Fig. 1C, the differences between WT and TG animals are less significant. At 9 months Fig. 1D, the difference in elimination of toxic A[3o (E22P) and pTauThr181 forms between WT and TG animals persists and increases. Similarly, at this age, a significant elimination of pre-fibrillar forms of A[3 (OC) is observed in TG animals.
[0090] In the insoluble fractions, an increase in the detection of Tau-PThr181, Tau-PThr205 and A[3-F (OC) proteins is observed in TG animals compared to WT animals at the age of 4 months Fig. 2B. From 6 months Fig. 2C and Fig. 2D, WT animals eliminate pTauThr181 in an identical manner, or even more pTauThr205 or A[3-F (OC) than transgenic animals.
[0091] In the brain, amyloid plaques are detected in the cortex and hippocampus in mice from 3 months of age. These observations are accompanied by morphological changes and a decrease in synapse density.
[0092] At the intestinal level, from 6 weeks, an accumulation of the toxic oligomeric form of A[3 (A[3o) and the pre-fibrillar form (A |3-F) is observed. However, there are no amyloid plaques at the intestinal level. This accumulation is associated with a disorganization of the epithelial barrier. These observations suggest a modification of the properties of the barrier leading to an alteration of the nutrient absorption capacities and / or the transit motility of TG mice and the development of an inflammatory context.
[0093] These results demonstrate that, unexpectedly, the gastrointestinal tract reflects what is happening in the brain at the level of A[3 and tau. According to the invention, solid molecular and histological changes are observed, heralding AD in the intestine, even before the appearance of the first symptoms, i.e. before any damage to the brain and specifically to this disease.
[0094] The use of feces compared to blood or saliva markers has the advantage of being much earlier and more sensitive (the A[3 peptides and the tau proteins eliminated are stable and in significant quantities).
[0095] The measurement of these markers in stools therefore constitutes a powerful tool for the early diagnosis of AD and monitoring of disease progression.
[0096] All these observations indicate that intestinal changes follow the progression of the AD brain. The intestine also reveals an accumulation of A[3 peptides and tau-phosphorylated proteins in the feces which was detected before any accumulation in the brain. Indeed, an accumulation and then a elimination of soluble proteins associated with intestinal morphological changes, followed by a clearance of insoluble proteins in the feces were observed.
Claims
Claims
1. Method for the in vitro diagnosis of a neurodegenerative disease, in a human or animal individual, comprising the step of detecting the presence of at least one marker chosen from beta-amyloid peptides (A[3), the forms derived from said peptides, phosphorylated tau proteins and the forms derived from said proteins, in a stool sample from said individual.
2. Method for the in vitro diagnosis of a neurodegenerative disease, at an early stage, in a human or animal individual, asymptomatic or not, comprising the step of detecting the presence of at least one marker chosen from beta-amyloid peptides (A[3), the forms derived from said peptides, phosphorylated tau proteins and the forms derived from said proteins, in a stool sample from said individual.
3. Method for the in vitro diagnosis of Alzheimer's disease, in a human or animal individual, comprising the step of detecting the presence of at least one marker chosen from beta-amyloid peptides (A[3), the forms derived from said peptides, phosphorylated tau proteins and the forms derived from said proteins, in a stool sample from said individual.
4. Method for the in vitro diagnosis of Alzheimer's disease, at an early stage, in a human or animal individual, asymptomatic or not, comprising the step of detecting the presence of at least one marker chosen from beta-amyloid peptides (A[3), the forms derived from said peptides, phosphorylated tau proteins and the forms derived from said proteins, in a stool sample from said individual.
5. Method according to any one of claims 1 to 4, for the in vitro diagnosis of a tauopathy, in a human or animal individual, comprising the step of detecting the presence of at least one marker chosen from phosphorylated tau proteins and their derived forms, in a stool sample from said individual.
6. Method according to any one of claims 1 to 5, characterized in that it comprises the following steps: said stool sample of said individual is brought into contact with at least one antibody or part of an antibody specifically recognizing at least one of said markers, under conditions allowing the formation of a complex between said antibody or part of antibodies and said marker, the presence of a said complex is detected, where appropriate, the presence of a said complex determining the individual's involvement by a neurodegenerative disease.
7. Method for monitoring the condition of a human or animal individual suspected of suffering from a neurodegenerative disease, said individual being able to be treated for said disease, comprising the following steps: a first stool sample from said individual is brought into contact in the presence of at least one antibody or part of an antibody specifically recognizing at least one marker chosen from beta-amyloid peptides (A[3), the derived forms of said peptides, phosphorylated tau proteins and the derived forms of said proteins, under conditions allowing the formation of a complex between said antibody or part of an antibody and said marker, the content of a said complex in the first sample is measured, then a second stool sample from said individual is brought into contact, said second sample being taken after the first sample, in the presence of said antibody or part of an antibody,under conditions allowing the formation of a complex between said antibody or part of antibody and said marker, the content of said complex in the second sample is measured, a variation between the contents of said complex in the first sample and of said complex in the second sample, indicating progression of the disease or regression of the disease.,
8. Method according to claim 7, characterized in that the antibody or part of antibody specifically recognizes at least one beta-amyloid peptide or a form derived from a soluble beta-amyloid peptide and forms a complex with it, and a content of said complex in the second sample higher than the content of this same complex in the first sample indicates progression of the disease, at an early stage, or a content of said complex in the second sample lower than the content of this same complex in the first sample indicates regression of the disease.
9. Method according to claim 7 or 8, characterized in that the antibody or antibody part specifically recognizes at least one soluble phosphorylated tau protein or a form derived from a phosphorylated tau protein and forms a complex therewith, and a content of said complex in the second sample higher than the content of the same complex in the first sample indicates progression of the disease, at an early stage, or a content of said complex in the second sample lower than the content of the same complex in the first sample indicates regression of the disease.
10. A method for screening a medicament for treating a neurodegenerative disease, in an individual suspected of suffering from such a disease, comprising the following steps: a first stool sample from said individual is brought into contact with at least one antibody or part of an antibody specifically recognizing at least one marker chosen from beta-amyloid peptides (A[3), the derived forms of said peptides, phosphorylated tau proteins and the derived forms of said proteins, under conditions allowing the formation of a complex between said antibody or part of an antibody and said marker, the content of said complex in the first sample is measured, then a second stool sample from said individual is brought into contact, said second sample being taken after the first sample, in the presence of said antibody or part of an antibody,under conditions allowing the formation of a complex between said antibody or part of antibody and said marker, the content of said complex in the second sample is measured, a variation between the contents of said complex in the first sample and of said complex in the second sample, indicating the effectiveness or ineffectiveness of said drug.,
11. Method according to claim 10, characterized in that the antibody or part of antibody specifically recognizes at least one beta-amyloid peptide or a derived form of a soluble beta-amyloid peptide and forms a complex with it, and the content of said complex in the second sample lower than the content of this complex in the first sample indicates an effectiveness of the drug.
12. A method according to claim 10 or 11, characterized in that the antibody or antibody part specifically recognizes at least one phosphorylated tau protein or a derived form of a soluble phosphorylated tau protein and forms a complex therewith, and a content of said complex in the second sample lower than the The content of this complex in the first sample indicates the effectiveness of the drug.
13. Kit for the in vitro detection of a neurodegenerative disease, at the early stage, of a human or animal individual, comprising at least one antibody or part of an antibody specifically recognizing at least one marker chosen from beta-amyloid peptides (A[3), the forms derived from said peptides, phosphorylated tau proteins and the forms derived from said proteins, and the means allowing the extraction, from a stool sample of said individual, of at least one marker chosen from beta-amyloid peptides (A[3), the forms derived from said peptides, phosphorylated tau proteins and the forms derived from said proteins, and the formation of a complex between said antibody or part of an antibody and said marker,
14. Use of a marker present in the stools of an individual and chosen from beta-amyloid peptides (A[3), forms derived from said peptides, phosphorylated tau proteins and forms derived from said proteins, for the in vitro diagnosis of a neurodegenerative disease in said individual.
15. Use according to claim 14, characterized in that the diagnosis is carried out at an early stage of the disease.
16. Use according to claim 14 or 15, characterized in that the neurodegenerative disease is Alzheimer's disease.
Citation Information
Patent Citations
Method for the diagnosis of amyloid-associated diseases
WO2019192969A1
Determination of disease-specific protein aggregates in stool samples
WO2021239700A2
